A Comparison of VerifyNow® with PlateletMapping® -Detected Aspirin Resistance and Correlation with Urinary Thromboxane
Authors:
- Roger C. CarrollRCRoger C. Carroll
- Robert M. CraftRCRobert M. Craft
- Carolyn C. SniderCSCarolyn C. Snider
- Venkata R. AligetiVAVenkata R. Aligeti
- Dale C. WorthamDWDale C. Wortham
- 1 February 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 116 (2) , 282-286
Abstract
Aspirin-resistant platelet activation in whole blood is attributable to a transcellular pathway not detected by isolated platelet aggregometry. Aspirin resistance as defined by urinary thromboxane levels is associated with increased risk for myocardial infarction or cardiac death. Whole blood point-of-care assays may also detect aspirin resistance. We compared PlateletMapping® with VerifyNow® for detecting aspirin resistance in 200 patients undergoing invasive cardiac procedures. This included 10 patients not receiving aspirin therapy for comparison. The assay results were correlated with urinary 11-dehydro-thromboxane B2 collected 2 to 8 hours after the procedure. PlateletMapping detected aspirin resistance in 32% of patients. VerifyNow detected aspirin resistance in 6% of patients. A patient's compliance with aspirin therapy was confirmed by a <20% aggregation response to arachidonic acid by light transmission aggregometry. Aspirin-resistant patients as determined by PlateletMapping had significantly (P<0.001) higher urinary 11-dehydro-thromboxane B2 levels than aspirin-sensitive patients but significantly (P=0.001) lower levels than patients not receiving aspirin therapy. There was no significant difference in urinary 11-dehydro-thromboxane B2 for aspirin-resistant compared with aspirin-sensitive patients as determined by VerifyNow, but the confidence intervals were wide. There was no significant correlation of resistance as defined by PlateletMapping with aspirin dose. However, there was significant increased aspirin sensitivity with clopidogrel (0.0006) or statin (0.004) cotherapies. There also was a significant correlation of smoking with aspirin resistance. These results indicate that PlateletMapping could be a useful point-of-care assay to identify aspirin-resistant patients for better perioperative risk stratification and management.Keywords
This publication has 19 references indexed in Scilit:
- Pravastatin and simvastatin improves acetylsalicylic acid‐mediated in vitro blood platelet inhibitionEuropean Journal of Clinical Investigation, 2012
- Post interventional cardiology urinary thromboxane correlates with PlateletMapping® detected aspirin resistanceThrombosis Research, 2010
- Carbon monoxide releasing molecule-2 increases the velocity of thrombus growth and strength in human plasmaBlood Coagulation & Fibrinolysis, 2009
- Aspirin Resistance and Adverse Clinical Events in Patients with Coronary Artery DiseaseThe American Journal of Medicine, 2007
- Overestimation of Platelet Aspirin Resistance Detection by Thrombelastograph Platelet Mapping and Validation by Conventional Aggregometry Using Arachidonic Acid StimulationJACC, 2005
- A Thrombelastograph whole blood assay for clinical monitoring of NSAID-insensitive transcellular platelet activation by arachidonic acidJournal of Laboratory and Clinical Medicine, 2005
- A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregationJournal of Laboratory and Clinical Medicine, 2004
- Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatmentJACC, 2004
- Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular EventsCirculation, 2002
- The aggregation of blood plateletsThe Journal of Physiology, 1963